The efficacy of 177 Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis
作者： Seong-Jang Kim , Kyoungjune Pak , Phillip J. Koo , Jennifer J. Kwak , Samuel Chang
DOI: 10.1007/S00259-015-3155-X
关键词: Radionuclide therapy 、 Disease 、 Octreotide 、 Gastroenterology 、 Clinical trial 、 Meta-analysis 、 Medicine 、 Confidence interval 、 Nuclear medicine 、 Internal medicine 、 Disease Response 、 Neuroendocrine tumors
摘要: This study was performed to evaluate the efficacy of 177Lu-labelled peptide receptor radionuclide therapy (PRRT) in patients with inoperable or metastatic neuroendocrine tumours (NETs). Systematic searches MEDLINE and EMBASE databases were using keywords “neuroendocrine”, “177Lu” “prognosis”. All published studies treated radiopharmaceuticals evaluated either Response Evaluation Criteria Solid Tumours (RECIST) 1.0 Southwest Oncology Group (SWOG) criteria both included. If there more than one from same institution, only report information most relevant this Each response group analysed for disease rates control rates, defined as percentages complete (CR) + partial (PR), CR + PR + stable (SD), respectively, a therapeutic intervention clinical trials anticancer agents. The pooled proportions are presented fixed-effects model random-effects model. Six 473 (4 RECIST 356 patients, 3 SWOG 375 1 groups) demonstrated ranging between 17.6 43.8 % effect 29 % [95 % confidence interval (CI) 24–34 %]. Disease ranged 71.8 100 %. showed an average rate 81 % (95 % CI 71–91 %). 7.0 36.5 % 23 % 11–38 %). 73.9 89.1 %. 82 % PRRT is effective treatment option NETs.
springer.com
sci-hub.se 参考文章(31)
Wout A.P. Breeman, Marion de Jong, Eric P. Krenning, Bert F. Bernard, Roelf Valkema, Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. The Journal of Nuclear Medicine. ,vol. 46, ,(2005)
E. P. KRENNING, P. P. M. KOOIJ, W. H. BAKKER, W. A. P. BREEMAN, P. T. E. POSTEMA, D. J. KWEKKEBOOM, H. Y. OEI, M. JONG, T. J. VISSER, A. E. M. REIJS, S. W. J. LAMBERTS, Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Annals of the New York Academy of Sciences. ,vol. 733, pp. 496- 506 ,(1994) , 10.1111/J.1749-6632.1994.TB17300.X
A. Otte, E. Jermann, M. Behe, M. Goetze, H. C. Bucher, H. W. Roser, A. Heppeler, J. Mueller-Brand, H. R. Maecke, DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 24, pp. 792- 795 ,(1997) , 10.1007/BF00879669
Giovanni Paganelli, Maddalena Sansovini, Alice Ambrosetti, Stefano Severi, Manuela Monti, Emanuela Scarpi, Caterina Donati, Annarita Ianniello, Federica Matteucci, Dino Amadori, 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 41, pp. 1845- 1851 ,(2014) , 10.1007/S00259-014-2735-5
Lisa Bodei, Mark Kidd, Giovanni Paganelli, Chiara M. Grana, Ignat Drozdov, Marta Cremonesi, Christopher Lepensky, Dik J. Kwekkeboom, Richard P. Baum, Eric P. Krenning, Irvin M. Modlin, Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 42, pp. 5- 19 ,(2015) , 10.1007/S00259-014-2893-5
Ebrahim S. Delpassand, Amin Samarghandi, Sara Zamanian, Edward M. Wolin, Mohammadali Hamiditabar, Gregory D. Espenan, Jack L. Erion, Thomas M. O’Dorisio, Larry K. Kvols, Jaime Simon, Robert Wolfangel, Arthur Camp, Eric P. Krenning, Alireza Mojtahedi, Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. ,vol. 43, pp. 518- 525 ,(2014) , 10.1097/MPA.0000000000000113
Phillip G. Claringbold, Paul A. Brayshaw, Richard A. Price, J. Harvey Turner, Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 38, pp. 302- 311 ,(2011) , 10.1007/S00259-010-1631-X
Marianne Pavel, Eric Baudin, Anne Couvelard, Eric Krenning, Kjell Öberg, Thomas Steinmüller, Martin Anlauf, Bertram Wiedenmann, Ramon Salazar, ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. ,vol. 95, pp. 157- 176 ,(2012) , 10.1159/000335597
D. J. Kwekkeboom, W. H. Bakker, B. L. Kam, J. J. M. Teunissen, P. P. M. Kooij, W. W. Herder, R. A. Feelders, C. H. J. Eijck, M. Jong, A. Srinivasan, J. L. Erion, E. P. Krenning, Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 30, pp. 417- 422 ,(2003) , 10.1007/S00259-002-1050-8
A. Romer, D. Seiler, N. Marincek, P. Brunner, M. T. Koller, Q. K. T. Ng, H. R. Maecke, J. Müller-Brand, C. Rochlitz, M. Briel, C. Schindler, M. A. Walter, Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 41, pp. 214- 222 ,(2014) , 10.1007/S00259-013-2559-8